WEGOVY Drug Patent Profile

When do Wegovy patents expire, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in two NDAs. There are eighteen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Wegovy

Wegovy was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2029. This may change due to patent challenges or generic licensing.

There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for WEGOVY

US Patents:	18
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for WEGOVY

Paragraph IV (Patent) Challenges for WEGOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WEGOVY	Tablets	semaglutide	25 mg	218316	1	2026-08-28
WEGOVY	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	218316	1	2026-03-11

US Patents and Regulatory Information for WEGOVY

WEGOVY is protected by twenty US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW STRENGTH.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-008	May 5, 2026		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes			Y

International Patents for WEGOVY

When does loss-of-exclusivity occur for WEGOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WEGOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	112480
Australia	2018321157
Australia	2024204151
Brazil	112020002804
Canada	3082033

Supplementary Protection Certificates for WEGOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	22/2018	Austria		PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	122018000075	Germany		PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	661	Finland

WEGOVY (semaglutide) investment scenario and fundamentals analysis: patent estate, exclusivity, FDA/IP risk, and growth-to-valuation drivers

Last updated: August 1, 2026

Executive summary

• Wegovy is the flagship FDA-approved once-weekly GLP-1 receptor agonist (semaglutide) for chronic weight management. The investment case depends on continued Medicare/Commercial formulary access, manufacturing scale-up, and the durability of U.S. IP and regulatory exclusivities that gate sub-2 mg and higher-dose supply expansions by competitors.
• The largest near-term risk is not “patentless” competition but constrained supply and payer friction that can cap volume growth before demand softens. The key mid-term risk is generic and biosimilar entry timing in the U.S., including Paragraph IV and potential injunction outcomes tied to the Orange Book patent list for Wegovy.
• For investors, the highest-signal fundamentals are: (1) U.S. prescription growth and share in anti-obesity medicine, (2) Medicare Part D and employer coverage breadth, (3) dose-mix improvements that raise revenue per patient, (4) margin trajectory from COGS and outsourcing transitions, and (5) litigation outcomes affecting exclusivity or enforcing specific formulation, method-of-use, or process patents.
• With limited disclosed quantitative fundamentals in the prompt, this analysis focuses on the investment-relevant IP and regulatory gatekeeping variables and the competitive structure that drive valuation ranges.

---

What patents protect Wegovy (semaglutide) in the US, and how many are in force?

Featured snippet answer: Wegovy’s U.S. protection is driven by a layered patent estate covering the semaglutide molecule, GLP-1 dosing regimens for weight management, and additional patents tied to specific dosage forms and manufacturing/process claims that are listed in the Orange Book for the Wegovy NDA.

How the Orange Book patent list typically maps to risk

Wegovy’s enforceable barriers to generic entry generally cluster into four buckets:

1. Active ingredient / drug substance (semaglutide composition).
2. Formulation and presentation (injectable composition, pen, cartridge, stabilizers, concentration).
3. Method of use (chronic weight management dosing regimens).
4. Manufacturing and process (synthetic routes, intermediates, purification steps, and formulation manufacturing processes).

Each bucket can independently support an injunction if asserted in litigation following an ANDA (generic) Paragraph IV filing.

Patent estate durability: what matters for investors

• Number of Orange Book-listed patents: more listed patents increases the probability that at least one asserted claim survives early motions or leads to a successful settlement with a delayed launch.
• Claim type: method-of-use and formulation patents can delay “design-around” even when generic entrants can match drug substance.
• Expiration spacing: staggered expiries reduce the chance of a single date that opens the floodgates.

Who usually holds the estate

Wegovy is marketed by Novo Nordisk in the U.S. The relevant Orange Book patents for Wegovy are generally held by the NDA holder and/or its affiliates and are commonly accompanied by continuation filings that extend claim coverage around formulation and dosing.

---

When does Wegovy lose exclusivity in the U.S., and what is the practical launch window for generics?

Featured snippet answer: Wegovy’s exclusivity and patent expiry determine the earliest U.S. generic launch date, but the practical window depends on which patents are listed for Orange Book purposes and which are successfully challenged or enforced in court.

Exclusivity vs. patent expiry: investors need both

• Regulatory exclusivity (data exclusivity and marketing exclusivity) can prevent FDA approval even if a patent expires.
• Patent expiration controls whether FDA can approve an ANDA but courts can still block launch via injunctions.

Paragraph IV outcomes shift “launch math”

Even when a generic files a Paragraph IV challenge, the final launch date can move by:

• Settlement agreements (often involving a “carve-out” launch date and sometimes non-infringement concessions).
• Court injunctions based on likelihood of success at early stages.
• Appeals that delay final resolution.

Practical investor takeaway

For valuation, a generic entrant’s “theoretical” date is less predictive than the combination of:

• Orange Book patent expiry calendar,
• Litigation schedule, and
• Whether settlements produce stipulated non-infringing launch terms.

---

How strong is the patent estate for Wegovy, and what claim categories dominate enforcement?

Featured snippet answer: Enforcement typically targets method-of-use dosing and injectable formulation features, because these claims can block patient use and can be harder to design around without changing dosage regimens or product specifications.

What investors watch in litigation dockets

• Early motion outcomes: motions to dismiss, claim construction results, and summary judgment rulings.
• Injunction scope: whether court orders cover specific dosages, specific claim sets, or all infringing versions.
• Claim survival rate: how many asserted claims remain after claim construction.

Design-around feasibility

In obesity GLP-1 products, “design-around” is often constrained by:

• Regulatory requirements for bioequivalence,
• Therapeutic equivalence expectations (dose and titration schedules),
• Injectable formulation performance constraints (stability, viscosity, device compatibility).

---

What generic entry risks exist for Wegovy (semaglutide), and which Paragraph IV filings matter?

Featured snippet answer: The key entry risk is ANDA Paragraph IV challenges to Orange Book-listed Wegovy patents. Launch timing is usually driven by settlements or injunctions tied to the patents asserted.

How Paragraph IV risk concentrates

Risk concentrates in patents that:

• Are asserted in litigation most often,
• Have strong infringement evidence (tight claim scope),
• Are difficult to design around without changing clinically relevant dosing or formulation attributes.

Bigger picture competitive pressure

Even if a generic launch is blocked, the presence of competing GLP-1 and GLP-1/GIP products can pressure price and formulary coverage. That is a commercial risk that can matter more than patent expiry in some quarters.

---

How does Wegovy compare with Ozempic and Rybelsus for exclusivity, patents, and investment exposure?

Featured snippet answer: Ozempic and Wegovy share semaglutide exposure, but differ in labeled indications, dosing regimens, and formulation/delivery. Patent and exclusivity leverage can therefore be indication- and presentation-specific.

Why comparisons matter to investors

• Method-of-use patents may be narrower to obesity indications for Wegovy.
• Even with shared drug substance, a competitor can face separate patent barriers for weight management dosing.
• Label differences can also affect payer strategy and switching behavior.

Investment sensitivity

• If payers treat Ozempic as a substitute, Wegovy’s volume can face pressure even without generic entry.
• If insurers restrict Ozempic coverage for obesity while covering Wegovy, Wegovy can retain share even if generic entry risk rises.

---

What formulations are protected by Wegovy patents, and what dose forms are at issue?

Featured snippet answer: Formulation protection commonly covers the semaglutide injectable composition and device deliverability for the Wegovy pen format, often tied to stability and concentration-specific composition claims.

Dose escalation and manufacturing linkage

For chronic weight management, the dosing ladder (titration across multiple strengths) creates multiple potential infringement surfaces:

• Device and pen compatibility at each concentration,
• Stability under storage conditions,
• Injectable performance (viscosity and delivery mechanics).

Manufacturing/process patents can block entry even when generic firms are able to match the drug substance.

---

What method-of-use patents protect Wegovy weight management regimens?

Featured snippet answer: Method-of-use patents generally cover dosing regimens for chronic weight management, including patient populations and titration schedules.

Why method-of-use matters

• An infringing generic can be blocked if its label or intended use falls within a claimed regimen.
• Courts can enforce even when drug substance is identical, because the “use” element is where infringement can be proven.

---

What is the Orange Book status of Wegovy, and how does it inform licensing and litigation?

Featured snippet answer: The Orange Book status informs which patents FDA requires to be listed for the NDA and therefore which patents a generic ANDA can challenge via Paragraph IV.

How Orange Book listings affect deal-making

Patent lists influence:

• Whether parties settle early,
• Whether a generic entrant seeks a design-around,
• Whether licensees obtain rights to specific claim categories (composition, formulation, method-of-use, process).

Litigation and licensing leverage

Orange Book-listed patents are the ones that drive ANDA litigation. For investors, the key is not the total number of semaglutide patents across portfolios but how many are Orange Book-listed for Wegovy and how those specific claims are litigated.

---

What patent litigation affects Wegovy, and what are the typical timelines investors should model?

Featured snippet answer: Litigation around Orange Book patents following Paragraph IV challenges typically spans claim construction, summary judgment phases, and potential appeals, with settlements often fixing a later “trigger date” for generic launch.

Timeline model (typical)

• Paragraph IV filing prompts FDA notice and triggers litigation.
• Early court phases can include dismissal/claim construction.
• Merits rulings determine injunction risk.
• Settlement resolves launch timing and design-around scope.
• Appeals can delay outcomes.

Investment modeling approach

The valuation should be tied to:

• Probability-weighted launch scenarios,
• Expected launch dates by dosage,
• Expected price erosion and margin impacts assuming coverage and switch rates.

---

How do payer coverage and supply constraints change Wegovy’s revenue trajectory?

Featured snippet answer: Wegovy’s growth is constrained less by demand at launch and more by payer coverage rules and manufacturing throughput at higher-dose strengths.

Key fundamentals investors track

• U.S. prescriptions and net sales (growth and market share).
• Dose-mix (share of patients on higher maintenance doses).
• Backorder and fulfillment metrics tied to manufacturing ramp.
• Formulary tiers and prior authorization intensity.
• Commercial vs Medicare share and restrictions.

Why this affects IP valuation

Even if IP blocks generics, commercial momentum can still be capped by:

• Supply limitations,
• Payer restrictions,
• Competitive pressure from alternative GLP-1 and incretin therapies.

---

Which companies are challenging Wegovy (generic/biosimilar risk), and how does competition affect IP value?

Featured snippet answer: Generic companies can pursue ANDA Paragraph IV for Wegovy if they identify Orange Book-listed patents to challenge. Competition from other branded GLP-1 products can pressure formulary decisions even without generic entry.

Commercial substitute risk

Substitutes can be:

• Other semaglutide products with different labels (indication switching),
• Tirzepatide-based therapies,
• Other incretin-based obesity treatments.

Investment consequence

If payers prefer substitutes due to price or coverage policies, Wegovy can face revenue share erosion even if generic entry is delayed.

---

What settlement agreements or licensing deals could move Wegovy’s generic launch dates?

Featured snippet answer: The most valuation-relevant events are settlements that set fixed launch dates for competing generics or specify design-around product constraints.

What to model in investment scenarios

• Launch date by strength (injection pens often have dosage-specific barriers).
• Geographic limits (U.S.-only agreements).
• Royalty structures that can mitigate revenue impacts through shared proceeds.
• Non-infringement covenants that enable partial or full launch.

---

What FDA regulatory status matters for Wegovy, and how does it gate generic approval?

Featured snippet answer: Wegovy’s NDA status, exclusivity protections, and Orange Book patent listings determine whether FDA can approve ANDAs for specific patent challenges and whether courts can block launch.

Key regulatory gateposts

• Whether the application is an ANDA (small molecule generics) versus other pathways.
• Whether the applicant is seeking approval for the same strengths and dosing scheme.
• Whether FDA can approve while litigation is pending.

---

How does Wegovy’s patent and regulatory profile compare with other GLP-1 anti-obesity therapies?

Featured snippet answer: Comparable incretin products vary in their Orange Book patent density, method-of-use claim breadth, and label-specific exclusivity. The competitive “launch risk” is therefore molecule-wide but also label- and formulation-specific.

Investor framework

• Identify which competitor has fewer enforceable Orange Book patents for the obesity indication.
• Compare the probability of successful Paragraph IV challenges.
• Compare settlement culture and historical time-to-resolution in comparable GLP-1 patent disputes.

---

Revenue exposure: what share of anti-obesity medicine value does Wegovy represent, and where is it most vulnerable?

Featured snippet answer: Wegovy’s revenue exposure is most vulnerable where payer restrictions reduce conversion to sustained maintenance dosing, and where substitute therapies gain coverage.

Vulnerable points

• High-cost therapies face tough utilization management.
• Dose escalation delays due to supply can temporarily reduce revenue per patient.
• Competitors with broader coverage can capture new starts.

Valuation implication

IP-driven generic risk can matter, but commercial coverage and supply dynamics can move revenue quarter-to-quarter.

---

Key Takeaways

• Wegovy’s investment fundamentals hinge on IP durability tied to Orange Book-listed patents (composition, formulation, and method-of-use) and the litigation outcomes that determine actual generic launch dates.
• Exclusivity and patent expiry are necessary inputs, but valuation is driven by settlement and injunction risk after Paragraph IV filings.
• The highest near-term commercial drivers are payer coverage, utilization management, and manufacturing throughput across the multi-strength dosing ladder.
• Competitive pressure from other incretin therapies can compress revenue and margin even without generic entry.

---

FAQs

1. What drives Paragraph IV litigation outcomes for Wegovy in U.S. courts?
   Key determinants are Orange Book patent claim scope, infringement evidence for dosing regimens or formulations, and claim construction outcomes.

2. Can a generic launch Wegovy-like semaglutide without infringing method-of-use patents?
   It depends on whether the proposed label and intended use fall outside the claimed dosing regimen and patient criteria.

3. How do payer restrictions and prior authorization affect Wegovy’s revenue growth more than patent risk?
   Utilization controls can limit patient starts and maintenance dosing, directly impacting volume and dose-mix, independent of generic launch timing.

4. Do manufacturing and process patents create barriers even when drug substance is identical?
   Yes. Process claims can block approval or use of manufacturing routes if found infringing, even when formulation and drug substance match.

5. What is the biggest investor signal to watch for Wegovy over the next 12 to 24 months?
   Quarterly indicators of U.S. prescription growth and dose-mix progression combined with fulfillment capacity and payer coverage changes.

---

References

No sources were provided in the prompt, and no Orange Book, FDA, or litigation docket details were included; therefore, no citations can be generated under the requirement to cite only cited sources.